Find a Clinical Trial

Showing 1 - 10 of 124 Trials

  • Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis A COG Groupwide Phase 2 Study

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05828069

    Population:

    Pediatrics/Adult

    Phase:

    II
    This trial is an open-label, multi-center Phase 2 study to evaluate the safety and efficacy of the pan-RAF inhibitor DAY101 in patients with relapsed/refractory LCH. The primary aim is to determine overall response rate for children and young adults with relapsed or refractory LCH treated with tovorafenib (DAY101) after 2 cycles and must be maintained 4 weeks later. Are you Eligible? (Inclusion Criteria) Age at diagnosis: 180 days- <22 years (at time of study enrollment) -Patients with multifocal progressive, relapsed, or recurrent LCH with measurable disease at study entry -Patients must...

  • A Phase II trial of avutometinib in combination with defactinib in metastatic diffuse gastric cancer

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06487221

    Population:

    Adult

    Phase:

    II
    There are two main types of stomach cancer based on the appearance under the microscope: intestinal-type and diffuse-type. Some stomach cancers also have a mix of intestinal-type and diffuse-type (mixed type). You are being invited to take part in this research study because you have been diagnosed with stomach cancer that has spread to other parts of the body and/or cannot be surgically removed, has diffuse-type or mixed-type cells or has gene alterations that are associated with diffuse-type stomach cancers (such as mutations in the genes CDH1 or RHOA), and you have already been treated...

  • A Phase 1 Study of PF-08046040/SEA-CD70 in MyeloidMalignancies

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04227847

    Population:

    Adult

    Phase:

    I
    You are being asked to participate in this study because you have Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and we are testing the study drug’s, SEA-CD70, to find out what its side effects are and to see if the study drug is safe for people with these types of cancer. are testing to see if SEA- CD70 is safe for people, and its side effects. SEA-CD70 is a type of drug called an antibody. Antibodies are part of your immune system. Usually they help protect you from getting sick. The purpose of this study is to use study drug SEA-CD70, and while using another antibody...

  • A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

    Principal Investigator:

    Peter Chei-Way Pan, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06860594

    Population:

    Adult

    Phase:

    I
    Researchers recently found that triapine can make radiation therapy work better against glioblastoma cells and in mice with glioblastoma. Tumors did not grow for a longer time after treatment with triapine along with radiation compared to radiation alone. Triapine has also been tested in people with other types of cancers and has been found to be safe. This study is being done to answer the following question: What is the highest dose of triapine that can be safely and tolerably taken in combination with radiation therapy in patients with recurrent glioblastoma or astrocytoma? We are doing...

  • A Phase 1 study of JNJ-95437446 in adult participants with advanced-stage solid tumors

    Principal Investigator:

    Lanyi Nora Chen, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07107230

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to investigate if the study drug JNJ-95437446 is safe and effective in treating patients with advanced-stage non-small cell lung cancer, colorectal cancer, and head and neck squamous cell cancer. This study will also find out if JNJ-95437446 can cause side effects. Side effects are unexpected or unwanted reactions from taking a drug. Another purpose is to find out how long JNJ-95437446 stays in your body and how your body responds to it. Are you Eligible? (Inclusion Criteria) Must be 18 years of age or older - Must be diagnosed with metastatic non-small cell lung...

  • A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with OsteosarcomaAn Intergroup NCTN Phase 3 Study

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05235165

    Population:

    Pediatrics/Adult

    Phase:

    III
    This study will be the first randomized controlled trial of surgical approach for pulmonary metastatic osteosarcoma. The study will randomize surgical resection of pulmonary metastases between Open surgery (thoracotomy or sternotomy) and minimally invasive Thoracoscopy. Primary outcome will be thoracic event free survival (thoracic event is defined as intrathoracic tumor recurrence by chest CT or death that results from the procedure or a complication related to the procedure). Correlative outcomes include quality of life from patient-reported outcomes, along with imaging and laboratory...

  • AGCT1532: Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT02582697

    Population:

    Pediatrics/Adult

    Phase:

    III
    This is a study for patients between 11 years and 45 years who have newly diagnosed intermediate or poor-risk metastatic germ cell tumors (GCTs). This study is looking at whether giving treatment with Bleomycin, Etoposide, and Cisplatin (BEP)every 2 weeks (accelerated BEP) or every 3 weeks (standard BEP) is better. Participants will be randomized to either Arm A: standard BEP or Arm B: accelerated BEP. All participants will receive a medication to stimulate the body to make white blood cells which has allowed some chemotherapy regimens to be given with a shorter than usual cycle length, while...

  • A MULTICENTER, OPEN-LABEL PHASE 1/1B/PHASE 2DOSE-FINDING, SAFETY, AND PHARMACOKINETICSTUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYLAURISTATIN E (MMAE) ANTIBODY DRUGCONJUGATE, IN ADVANCED REFRACTORYSOLID TUMORS

    Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06014658

    Population:

    Adult

    Phase:

    I
    The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans. Are...

  • PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTSWITH SYMPTOMATIC MULTIPLE MYELOMA

    Principal Investigator:

    Rajshekhar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05828511

    Population:

    Adult

    Phase:

    I/II
    This study is looking at people who have recently been newly diagnosed with a type of cancer called multiple myeloma (NDMM). The purpose of this study is to learn about the safety, tolerability (how your body reacts to the study drug), and effectiveness (tumor shrinkage) of linvoseltamab (called “study drug”) in participants with NDMM as a first step in determining if the study drug has a role to play in the treatment of NDMM. This study consists of 2 phases. Your study doctor will tell you which phase of the study you will be participating in. Are you Eligible? (Inclusion...

  • ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

    Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06172296

    Population:

    Pediatrics/Adult

    Phase:

    III
    This randomized study will evaluate the efficacy of a frontline chemoimmunotherapy Induction regimen versus a standard chemotherapy-only Induction regimen that reserves chemoimmunotherapy only for poor responders. This Phase 3 randomized study seeks to determine if the early addition of the anti-GD2 monoclonal antibody, dinutuximab, plus sargramostim, to standard COG Induction improves EFS for patients with newly diagnosed HRNBL. All patients will receive the same Induction Cycle 1 while their tumors undergo centralized molecular testing. Patients will then be randomized to receive either...

Pages

Back to top